

Exemplar clinical pathways for the stratification of cardiovascular disease

Thursday 17 March 2016, 12.30 – 17.10

Royal College of Nursing, 20 Cavendish Square, London, W1G 0RN

12.30-13.00	Lunch
13.00-13.05	Welcome Professor Peter Weissberg FMedSci (Chair), Medical Director, British Heart Foundation
13.05-13.20	Introducing NHS England's Personalised Medicine Strategy Professor Sue Hill OBE, Chief Scientific Officer, NHS England
13.20-13.35	Stratification of familial hypercholesterolaemia <i>The genetics of familial hypercholesterolaemia and possible interventions</i> Professor Steve Humphries FMedSci, Director of the Centre for Cardiovascular Genetics, University College London
13.35-13.50	A national approach to familial hypercholesterolaemia <i>An overview of the current systems for familial hypercholesterolaemia and barriers to adoption</i> Professor Huon Gray, National Clinical Director for Heart Disease, NHS England
13.50-14.50	Discussion session 1 Participants will be asked to discuss the high-level clinical pathway for the stratified diagnosis and treatment of familial hypercholesterolaemia, considering the key risks and barriers faced in implementing this pathway. Participants will also be asked to identify further key steps to refine this pathway in practice. It is expected that the discussion will cover: <ul style="list-style-type: none"> • Alignment of the diagnostics and therapeutics pathways, including guidance on use of diagnostics. • CCG commissioning and in particular, the commissioning and funding framework for diagnostics. • Other infrastructure considerations, including how existing initiatives (e.g. NHS GMCs, DECs, the precision medicine catapult) will contribute to any pathway. • Health economics: the strengths and weaknesses of the current evidence base on clinical-and cost-effectiveness. • Building capacity and capability, and integration of expertise.
14.50-15.10	Refreshment break
15.10-15.30	A stratified approach to inherited cardiac conditions <i>An overview of certain inherited cardiac conditions and the current approaches to stratifying patients, focused on hypertrophic cardiomyopathy and long QT syndrome</i> Professor Hugh Watkins FMedSci, Professor of Cardiovascular Medicine, University of Oxford
15.30-17.10	Discussion session 2 Participants will be asked to discuss the high-level clinical pathways for the stratified diagnosis and treatment of hypertrophic cardiomyopathy, long QT syndrome and Marfan syndrome, using the strategy for familial hypercholesterolaemia as an exemplar for these areas. Participants will again consider the key risks and barriers, and next steps for implementation.
17.10	Close